Soligenix's hybryte(tm) treatment now within reach for rare cancer patients

Hybryte(tm) nda anticipated in h2 2022new york, new york--(newsfile corp. - july 26, 2022) - pcg digital -- late-stage biopharmaceutical company, soligenix, inc. (nasdaq: sngx), has completed the largest placebo controlled, randomized phase 3 trial ever done in cutaneous t-cell lymphoma (ctcl) evaluating a novel topical treatment for early-stage ctcl and is preparing to submit a new drug application to the fda to commercialize the product.
SNGX Ratings Summary
SNGX Quant Ranking